Applied Therapeutics appoints Les Funtleyder as CFO effective Nov 20, 2023

Applied Therapeutics, Inc.

Funtleyder receives $525k base salary, 40% target bonus, and 300,000 RSUs vesting over 2 years.
Catherine Thorpe ceases as interim principal financial officer; remains Chief Accounting Officer.
Severance includes 3 months base salary, 3 months COBRA, prorated bonus, and full equity vesting upon qualifying termination.
Good reason for resignation defined as >10% salary cut, material duty reduction, or relocation >50 miles.
Employment at-will; cause defined as felony, fraud, material breach of duties.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Les Funtleyder

Chief Financial Officer

Applied Therapeutics, Inc.

Effective: 2023-11-20
Filed: November 17, 2023, 6:59 PM ET

appointed Les Funtleyder as Chief Financial Officer and principal financial officer of the Company, effective as of November 20, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Les Funtleyder was appointed as Chief Financial Officer at Applied Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

appointed Les Funtleyder as Chief Financial Officer and principal financial officer of the Company, effective as of November 20, 2023

View on SEC.gov

Source: SEC EDGAR

accession 0001104659-23-119514

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.